Latest news with #Trisomy21
Newsweek
2 days ago
- Health
- Newsweek
Mom Gives Birth to Baby at 33 Weeks, Then Gets Diagnosis
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. A mom from the North of England, U.K., received a shocking diagnosis after giving birth prematurely. Lauren Thomson (@laurenlou9x) shared a clip on TikTok and revealed that her baby boy was born at 33 weeks. Days later, she learned that her son has trisomy 21, also known as Down syndrome. Split view of premature baby boy and mom Lauren Thomson, 30, wearing brown leather-look jacket. Split view of premature baby boy and mom Lauren Thomson, 30, wearing brown leather-look jacket. @laurenlou9x The mom of four told Newsweek that her pregnancy came as a surprise itself. "I didn't find out I was pregnant until 16 weeks," she said. "I had no symptoms or signs of pregnancy. I had no idea that I was going to have him early and no scans showed anything different to my other children." Trisomy 21, or Down syndrome, is a genetic condition caused by the presence of an extra copy of chromosome 21. It can result in developmental delays, characteristic facial features and an increased risk of certain health conditions. However, the severity and symptoms vary widely between individuals. Thomson's son was immediately admitted to the neonatal unit after he was born. "He has been looked after on 24-hour care," Thomson told Newsweek, adding that hospital staff have been amazing. "They check his obs regularly and feed him like their own," she said. But it wasn't until four days after delivery that doctors raised concerns. Nurses had noticed several physical markers often associated with Down syndrome, such as low muscle tone, a folded ear and almond-shaped eyes. "That's when they discussed... testing him, which I agreed to after they explained the reasons," Thomson said. "I was very confused and shocked when they told me about it all; I didn't really know what to say or think." Thomson wrote on the text overlay of her clip that she "knows very little" about trisomy 21. "It was the strangest situation I've ever been in," she told Newsweek. "I just agreed with them about testing him and then went home and did some research about what had been said." Thomson's clip has been viewed more than 650,000 times and received almost 20,000 likes. Hundreds have commented with overwhelming support and many others shared their own experiences with Down syndrome. "My son was born in 2017 with trisomy 21 and I can promise you that he will teach you to see the world in completely new colors," one user wrote. "Congratulations. My 6yo little girl surprised us with an extra chromosome too, she's the best thing that's ever happened to me. I found it helpful to reach out to other parents and we were welcomed into the DS [Down syndrome] community with open arms," another said.
Glasgow Times
24-06-2025
- Health
- Glasgow Times
Refurbished playroom making big difference at Glasgow hospital
The facility at the Royal Hospital for Children offers a safe, stimulating environment tailored to each child's needs. It can be adjusted to cater to a range of abilities and preferences, serving as a space for movement and physiotherapy or a calming retreat for children with neurodiverse conditions. Alfie and his mum (Image: Supplied) The room, originally established in 2015, was funded by the McIntyre family in memory of their daughter Chloe. It continues to be known as Chloe's Room, with a plaque of acknowledgement above the door. Read more: Former Rangers coach takes up key role at English club with return on the cards Takeover complete as football club set for new era Cllr Susan Aitken: The deaths of Kory, Amen, and Kayden are three deaths too many This year, the room was transformed with funding from the Glasgow Children's Hospital Charity and the creativity of the hospital's play team. Wendy McKechnie, health play assistant, said: "The children got so much out of the room that already existed, and we knew that a refresh with some of the latest technologies would have a big impact. Alfie (Image: Supplied) "Thanks to the support of Glasgow Children's Hospital Charity, we've created a space that truly enhances the hospital experience. 'For children going through difficult treatments, even a short visit to the sensory room can lift their spirits. It's also a valuable tool for physiotherapy as children can be more relaxed and engaged, making therapy more effective and enjoyable.' The room features an Omi Vista interactive projector, which displays colourful games on the floor that respond to movement. This, along with touchpad mats that make sounds with movement, bubble tubes, and LED lights, provides visual and tactile stimulation for children with limited mobility. Julia-Grace with light squares (Image: Supplied) Amanda Kelso, mum of patient Alfie, said: "Alfie has Trisomy 21 and is peg-fed, so physiotherapy is a big part of his care. "Doing sessions in the sensory room helps keep him engaged and gives him a welcome change of scenery. "After three months in the hospital, that variety means a lot.' Stephanie Jack, mum of Julia-Grace, said: 'Julia-Grace has gone from going to school and attending clubs with her friends, to being in hospital for the past few months, so having any kind of distraction and a change of scenery keeps her going. "It's great to have space where she can play or just chill out. 'She loves playing with the floor projections, and the Play Team are excellent at making the games appropriate for each child too.'
Irish Independent
17-06-2025
- Sport
- Irish Independent
Meet the Wexford father undertaking a marathon fundraiser inspired by his daughter's 21st birthday
Jennie was born with Down syndrome (Trisomy 21) and is the inspiration behind Andrew undertaking three marathon challenges with the goal of raising €210,000 for Wexford Special Olympics Club and Windmill Therapeutic. "When Jennie was born, myself and my wife wouldn't have known much about Trisomy 21,' Andrew concedes. 'She had major heart surgery when she was just four months old and we didn't get her home from the hospital until she was eight months. "She has thrived since then though and she's still very healthy. She still sees a heart specialist for a check up every couple of years, but she's very active and she's been involved with Wexford Special Olympics club since she was 9, taking part in all kinds of competitions.' Clearly very proud of his girl, she has inspired Andrew to attempt three massive challenges in the coming months. This Saturday, on June 21, he will complete a 21 hour challenge at Rosslare Strand – swimming 2.1 miles, cycling 210 miles and running 21 miles. On September 21, he will attempt to complete Ironman Wales. The race is in the top 10 hardest Ironman races in the world with over 8,700ft of elevation during a 3.8km swim, 180km bike race and 42km run. Finally on October 26, he will attempt to complete the Dublin City Marathon in 3 hours and 47 minutes – the three representing the 3rd copy of chromosome 21 a child with Down syndrome is born with and the 47 representing the number of chromosomes in the body of a person with Downy syndrome. Currently racking up 20 hours a week, Andrew never loses sight of why he's doing it as Jennie is at his side all the way. "She's super excited,' the Tagoat father says. 'She'll come out with me on the bike sometimes when I'm out for a run and she helps me with the updates on Facebook and that type of thing. She can't wait for June 21st for things to get started.' While Andrew is working up a sweat, a day of family fun will take place in Rosslare Strand with a marquee set up on the green. People are invited to come out and cheer him on, enjoy a barbecue, buy a raffle ticket, enjoy the kids entertainment and maybe even join him for a mile or two of a run. "I would've done a good few big races before Covid, but not much since,' Andrew says with excitement setting in. ADVERTISEMENT Learn more "I came up with this idea about two years ago. Jennie's 21st was approaching and I wanted to do something big.' "I started training for this back in January and I'm 21 or 22 weeks in now. My attitude is to focus on the first challenge first and then build up slowly but surely. I did a little trial run of 16 hours last week, starting off in the sea at 3.30 a.m. It gave me a good idea of what it will be like.' With a significant target of €210,000, Andrew is hoping that people will really row in behind him and help him make a lasting difference to Wexford Special Olympics Club and Windmill Therapeutic, who provide day supports for adults with mild to moderate intellectual disabilities. "Jennie loves the community aspect of the Special Olympics Club,' Andrew explains. 'Just to be able to get involved, it means the world to her. It's a fantastic club and really opens doors for kids like Jennie and creates a sense of community and belonging for them. She has some great friends through the club. "As for Windmill, that's where she'll spend the next twenty, thirty, forty years of her life. They provide an amazing services and teach their clients life skills like how to budget and mind their money, how to get jobs and basically how to fend for themselves and enjoy some independence. "I know they are struggling for money. They are planning a huge renovation to create sensory rooms etc down there and they're trying to raise €300,000. I'm hoping that I'll be able to help them out with that. Andrew's fundraiser has already raised nearly €20,000 online alone and he's hopeful that people will turn out and join in the fun at Rosslare Strand on Saturday. To support Andrew and Jennie's fundraiser efforts, you can search for 3 for 21 – Trisomy 21 Fundraiser Challenge on iDonate. All donations are greatly appreciated.
Business Wire
27-05-2025
- Business
- Business Wire
Results of Aelis Farma Combined General Meeting of May 27, 2025
BORDEAUX, France--(BUSINESS WIRE)--Regulatory News: Aelis Farma (ISIN: FR0014007ZB4 – Ticker: AELIS), clinical-stage biopharmaceutical company specializing in the development of treatments for brain and peripheral diseases involving the CB 1 receptor, announces that all the resolutions recommended by the Board of directors were adopted by the Combined General Meeting of shareholders. Aelis Farma held its combined general meeting of shareholders on May 27, 2025, which was chaired by Mr. Anders Gersel Pedersen, Chairman of the Board of directors. With a quorum of 74.42 %, the shareholders have adopted all the resolutions recommended by the Board of Directors, in particular the financial statements for the 2024 financial year, the compensation policy applicable to the Chairman, the Chief Executive Officer and the directors, as well as delegations granted to the Board of directors related to financial transactions. The General Assembly also renewed the term of office of all the directors. Mr. Anders Gersel Pedersen was reappointed as Chairman of the Board of Directors. Detailed results of the vote on all resolutions, as well as the recording of the general meeting, will be available on the Company's website within the legal time frame. About AELIS FARMA Founded in Bordeaux in 2013, Aelis Farma is a biopharmaceutical company that is developing a new class of drugs, the Signaling Specific inhibitors of the CB 1 receptor of the endocannabinoid system (CB 1 -SSi). CB 1 -SSi have been developed by Aelis Farma based on the discovery of a natural regulatory mechanism of CB 1 hyperactivity made by the team led by Dr Pier Vincenzo Piazza, the Company's CEO, when he was the director of the Neurocentre Magendie of INSERM in Bordeaux. By mimicking this natural mechanism, CB 1 -SSi appear to selectively inhibit the disease-related activity of the CB 1 receptor without disrupting its normal physiological activity. CB 1 -SSi have consequently the potential to provide new safe treatments for several brain and peripheral organ diseases. Aelis Farma currently has two first-in-class clinical-stage drug candidates. AEF0117 for the treatment of cannabis use disorders (CUD), that has shown to be able to decrease cannabis use across two studies. AEF0217 for cognitive disorders, which has shown in a Phase 1/2 to be safe and able to improve adaptive behaviour in young adults with Down syndrome (Trisomy 21). The clinical results obtained with these 2 molecules have confirmed the pharmacological activity of CB 1 -SSi in humans. The Company also has a portfolio of new innovative CB 1 -SSi for the treatment of other disorders associated with a dysregulation of the activity of the CB 1 receptor, including diseases involving peripheral organs, such as obesity and related metabolic conditions. The different drugs developed by the company belong to the same general pharmacological class, the CB 1 -SSi, but have distinct functional effects allowing to target different types of dysregulations of the CB 1 receptor and guaranteeing that the different compounds are not substitutable one with the others. Aelis Farma draws on the talents of more than 25 highly qualified employees. For more information, visit and follow us on LinkedIn and Twitter. ISIN: FR0014007ZB4 Ticker: AELIS B Compartment of Euronext Paris Disclaimer Forward-looking statements Some information contained in this press release is forward-looking statements, not historical data. These forward-looking statements are based on current beliefs, expectations, and assumptions, including, but not limited to, assumptions about Aelis Farma's current and future strategy and the environment in which Aelis Farma operates. They involve known and unknown risks, uncertainties, and other factors, which may cause actual results, performance, achievements, or industry results or other events, to differ materially from those described or implied by such forward-looking statements. These risks and uncertainties include those set out and described in detail in Chapter 3 "Risk Factors" of Aelis Farma's Universal Registration Document filed with the Autorité des Marchés Financiers on April 28, 2025, under number D-25.0314. These forward-looking statements are made only as of the date of this press release and Aelis Farma expressly disclaims any obligation or undertaking to release any updates or corrections to the forward-looking statements included in this press release to reflect any change in expectations or events, conditions, or circumstances on which any such forward-looking statement is based. Forward-looking information and statements are not guarantees of future performance and are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond Aelis Farma's control. Actual results could differ materially from those described in, or implied or projected by, forward-looking information and statements.
Yahoo
27-05-2025
- Business
- Yahoo
Results of Aelis Farma Combined General Meeting of May 27, 2025
BORDEAUX, France, May 27, 2025--(BUSINESS WIRE)--Regulatory News: Aelis Farma (ISIN: FR0014007ZB4 – Ticker: AELIS), clinical-stage biopharmaceutical company specializing in the development of treatments for brain and peripheral diseases involving the CB1 receptor, announces that all the resolutions recommended by the Board of directors were adopted by the Combined General Meeting of shareholders. Aelis Farma held its combined general meeting of shareholders on May 27, 2025, which was chaired by Mr. Anders Gersel Pedersen, Chairman of the Board of directors. With a quorum of 74.42 %, the shareholders have adopted all the resolutions recommended by the Board of Directors, in particular the financial statements for the 2024 financial year, the compensation policy applicable to the Chairman, the Chief Executive Officer and the directors, as well as delegations granted to the Board of directors related to financial transactions. The General Assembly also renewed the term of office of all the directors. Mr. Anders Gersel Pedersen was reappointed as Chairman of the Board of Directors. Detailed results of the vote on all resolutions, as well as the recording of the general meeting, will be available on the Company's website within the legal time frame. About AELIS FARMA Founded in Bordeaux in 2013, Aelis Farma is a biopharmaceutical company that is developing a new class of drugs, the Signaling Specific inhibitors of the CB1 receptor of the endocannabinoid system (CB1-SSi). CB1-SSi have been developed by Aelis Farma based on the discovery of a natural regulatory mechanism of CB1 hyperactivity made by the team led by Dr Pier Vincenzo Piazza, the Company's CEO, when he was the director of the Neurocentre Magendie of INSERM in Bordeaux. By mimicking this natural mechanism, CB1-SSi appear to selectively inhibit the disease-related activity of the CB1 receptor without disrupting its normal physiological activity. CB1-SSi have consequently the potential to provide new safe treatments for several brain and peripheral organ diseases. Aelis Farma currently has two first-in-class clinical-stage drug candidates. AEF0117 for the treatment of cannabis use disorders (CUD), that has shown to be able to decrease cannabis use across two studies. AEF0217 for cognitive disorders, which has shown in a Phase 1/2 to be safe and able to improve adaptive behaviour in young adults with Down syndrome (Trisomy 21). The clinical results obtained with these 2 molecules have confirmed the pharmacological activity of CB1-SSi in humans. The Company also has a portfolio of new innovative CB1-SSi for the treatment of other disorders associated with a dysregulation of the activity of the CB1 receptor, including diseases involving peripheral organs, such as obesity and related metabolic conditions. The different drugs developed by the company belong to the same general pharmacological class, the CB1-SSi, but have distinct functional effects allowing to target different types of dysregulations of the CB1 receptor and guaranteeing that the different compounds are not substitutable one with the others. Aelis Farma draws on the talents of more than 25 highly qualified employees. For more information, visit and follow us on LinkedIn and Twitter. ISIN: FR0014007ZB4Ticker: AELISB Compartment of Euronext Paris Disclaimer Forward-looking statements Some information contained in this press release is forward-looking statements, not historical data. These forward-looking statements are based on current beliefs, expectations, and assumptions, including, but not limited to, assumptions about Aelis Farma's current and future strategy and the environment in which Aelis Farma operates. They involve known and unknown risks, uncertainties, and other factors, which may cause actual results, performance, achievements, or industry results or other events, to differ materially from those described or implied by such forward-looking statements. These risks and uncertainties include those set out and described in detail in Chapter 3 "Risk Factors" of Aelis Farma's Universal Registration Document filed with the Autorité des Marchés Financiers on April 28, 2025, under number D-25.0314. These forward-looking statements are made only as of the date of this press release and Aelis Farma expressly disclaims any obligation or undertaking to release any updates or corrections to the forward-looking statements included in this press release to reflect any change in expectations or events, conditions, or circumstances on which any such forward-looking statement is based. Forward-looking information and statements are not guarantees of future performance and are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond Aelis Farma's control. Actual results could differ materially from those described in, or implied or projected by, forward-looking information and statements. View source version on Contacts AELIS FARMA Pier Vincenzo PiazzaChief Executive Officercontact@ NewCap Dusan Oresansky / Aurélie ManavarereInvestor Relationsaelis@ +33 1 44 71 94 92 NewCap Arthur RouilléMedia Relationsaelis@ +33 1 44 71 00 15
